The Effect of Plant Sterol Supplement on Blood Cholesterol

This study is currently recruiting participants.

Verified by Rikshospitalet HF, May 2007

Sponsors and Collaborators:	Rikshospitalet HF Mills DA
Information provided by:	Rikshospitalet HF
ClinicalTrials.gov Identifier:	NCT00485095

Purpose

The purpose of this study is to determine whether supplement of plant sterol could lower blood cholesterol.

Condition	Intervention	Phase
High Blood Cholesterol Level	Behavioral: Intake of plant sterols	Phase IV

Genetics Home Reference related topics: hypercholesterolemia

MedlinePlus related topics: Cholesterol Dietary Supplements

Drug Information available for: Cholest-5-en-3-ol (3beta)-

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Official Title:	A Single Centre, Randomized Crossover Double-Blind Placebo-Controlled Study to Measure the Effect of Plant Sterol Supplement on Blood Cholesterol

Further study details as provided by Rikshospitalet HF:

Primary Outcome Measures:

Study Start Date:

January 2007

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

BMI at or above 35 kg/m2
Secondary hyperlipidemia, included diabetes
Hypertension (at og higher than 170/110)
Coronar, perifery or cerebral vascular disease last 3 months
Familial hypercholesterolemia
Change in dose of statins, oestrogen or contraceptives last 3 months
Taking drugs which are known to interfere with the plasma level of cholesterol
Chronic rheumatoid diseases or other diseases known to affect c-reactive protein
Pregnancy
Lactation
Planning to reduce weight
Taking plant sterols

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00485095

Contacts

Contact: Leiv Ose, MD

Locations

Norway
Rikshospitalet Radiumhospitalet HF, Oslo, Norway	Recruiting
Oslo, Norway
Contact: Leiv Ose, MD leiv.ose@rikshospitalet.no
Lipidklinikken, Rikshospitalet Radiumhospitalet HF	Recruiting
Oslo, Norway
Contact: Leiv Ose, MD leiv.ose@rikshospitalet.no

Sponsors and Collaborators

Rikshospitalet HF

Mills DA

Investigators

Principal Investigator:

Leiv Ose, MD

Lipidklinikken, Rikshospitalet-Radiumhospitalet HF

More Information

Study ID Numbers:	2.2006.3407
Study First Received:	June 11, 2007
Last Updated:	June 11, 2007
ClinicalTrials.gov Identifier:	NCT00485095
Health Authority:	Norway: The National Commitees for Medical Research Ethics

Study placed in the following topic categories:

Metabolic Diseases
Hyperlipidemias
Metabolic disorder

Hypercholesterolemia
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009